1. Aberegg SK, Hersh AM, Samore MH (2018) Empirical consequences of current recommendations for the design and interpretation of noninferiority trials. J Gen Intern Med 33(1):88–96
2. Bratton DJ, Williams HC, Kahan BC, Phillips PP, Nunn AJ (2012) When inferiority meets non-inferiority: implications for interim analyses. Clin Trials 9(5):605–609
3. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA et al (2013) SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 346:e7586
4. Committee for Proprietary Medicinal Products (2000) Points to consider on switching between superiority and non-inferiority. https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-switching-between-superiority-non-inferiority_en.pdf
5. Committee for Proprietary Medicinal Products (2002) Points to consider on multiplicity issues in clinical trials. https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-multiplicity-issues-clinical-trials_en.pdf